AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03574402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1.25g/m\^2 iv gtt. on day1,8. 21 days as one cycle.
Study NCT03574402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC5 iv gtt. Q3W on day1. 21 days as one cycle.
Study NCT02169856 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EFTs (emotional freedom techniques)
Description: The Emotional Freedom Techniques (EFTs) which has been pioneered by Gary Craig is a form of alternate medicine which works by tapping on body energy meridian points. Unlike drugs the EFTs has no side effects too
Study NCT02169856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tab. Midazolam 7.5 mg
Description: Tab. Midazolam 7.5 mg will be given to all patients at night before surgery.
Study NCT02169856 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tab. Midazolam 7.5 mg
Description: Tab. Midazolam 7.5 mg will be given to all patients at night before surgery.
Study NCT02169856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inj. Midazolam 0.7mg/kg
Description: Inj . Midazolam 0.7 mg/kg given as premedication 45 min before surgery.
Study NCT02169856 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Inj. Midazolam 0.7mg/kg
Description: Inj . Midazolam 0.7 mg/kg given as premedication 45 min before surgery.
Study NCT02169856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inj. Propofol 2.5mg/kg
Description: It was given to induce anesthesia after 3 min of pre oxygenation.
Study NCT02169856 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Inj. Propofol 2.5mg/kg
Description: It was given to induce anesthesia after 3 min of pre oxygenation.
Study NCT02169856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inj. Atracurium 0.5 mg/kg
Description: It was given to induce muscle relaxation during anesthesia
Study NCT02169856 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Inj. Atracurium 0.5 mg/kg
Description: It was given to induce muscle relaxation during anesthesia
Study NCT02169856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane 2.5 vol %
Description: It was given to maintain anesthesia during surgery alongwith oxygen in air mixture
Study NCT02169856 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sevoflurane 2.5 vol %
Description: It was given to maintain anesthesia during surgery alongwith oxygen in air mixture
Study NCT02169856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inj. Cefuroxime 1.5 g IV
Description: It was given as prophylactic antibiotic. 2 doses given. 1st 30-60 min before surgery. 2nd 6 hours after surgery
Study NCT02169856 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Inj. Cefuroxime 1.5 g IV
Description: It was given as prophylactic antibiotic. 2 doses given. 1st 30-60 min before surgery. 2nd 6 hours after surgery
Study NCT02169856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Inj. Ketorolac 30 mg IV
Description: 3 doses for analgesia. 1st immediate postoperative, 2nd at 8 hours postoperative and 3 rd at 16 hours postoperative period
Study NCT02169856 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Drug: Inj. Ketorolac 30 mg IV
Description: 3 doses for analgesia. 1st immediate postoperative, 2nd at 8 hours postoperative and 3 rd at 16 hours postoperative period
Study NCT02169856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inj. Zantac 50mg IV
Description: 2 doses. 1st at immediate postoperative and 2nd 12 hours after surgery
Study NCT02169856 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Inj. Zantac 50mg IV
Description: 2 doses. 1st at immediate postoperative and 2nd 12 hours after surgery
Study NCT03599479 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality group
Description: Virtual reality group The study intervention is to provide acute pain management for the subject undergoing fluoroscopic pain intervention by using the virtual reality program provided by the collaborator through virtual reality device (headset, headphone, and smartphone) that are commercialized on the market.
Study NCT01150968 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: End of life education
Description: Residents will participate in one hour, case-based, interactive teaching sessions on end of life communication.
Study NCT00166504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: atorvastatin 10 mg
Study NCT00100542 — intervention group
Intervention type: BEHAVIORAL
Intervention: Psychiatric interviews
Description: Measures and questionnaires regarding mental health, pain, and adherence to treatment. No actual treatment or intervention is given as part of this study.
Study NCT04382209 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: The transducer was placed vertically 3cm lateral to the midline to visualize the muscles of the back, transverse process and the pleura in between the two transverse processes. Bilateral ultrasound guided erector spinae plane block with 20 mL of 0.375% bupivacaine each using an in-plane, cranial-to-caudad approach to contact the bony shadow of the transverse process (TP) with the tip deep to the fascial plane of the erector spinae muscle. The correct location of the needle tip was confirmed by injecting 0.5-1 cc of normal saline 0.9% and observing linear fluid spread lifting the erector spinae muscle off the tip of the TP.
Study NCT04382209 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Intravenous meperidine patient controlled analgesia device
Description: Intravenous meperidine patient controlled analgesia device will be given to the patients postoperatively and 24 hour meperidine consumption will be recorded
Study NCT01343940 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project dulce
Description: Participating families are assigned to a legal/developmental specialist who joins health care team during well-child visits and home visits. The specialist (a Dulce family partner) supports parent around child development issues, addresses unmet basic needs (e.g., housing, utilities, food, etc.), and makes referral to existing agencies and services. Specialist meets with family during all routine well-child visits scheduled in primary care between birth and 6 months (1-mo, 2-mo, 4-mo, 6-mo). Parent may meet with specialist before or after scheduled appointment, and may request a home visit. Specialist will be available by phone for consultation.
Study NCT01343940 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Safety intervention
Description: Participating family is assigned a safety specialist. Meeting with the safety specialist will occur before or after a routine well-child visit or at a separately agreed upon time. The specialist will discuss infant injury risks associated with transportation and sleep. The specialist will provide safety equipment (car seat and pack-and-play) and instruct the parent in their proper use.
Study NCT01716585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267, ABT-333
Description: ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
Study NCT04303299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral
Description: Anti virus treatment
Study NCT00003799 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgery
Study NCT00262509 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Egress Badge
Description: Egress Badge is worn by subjects who are asked to use the badge to exit the building. The badge indicates the direction of each exit sign on route to an exit.
Study NCT00780325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG100649 (2 mg)
Description: CG100649 capsules: 2 mg, single oral administration (Part 1); CG100649 capsules: dose to be determined, single oral administration (the single CG100649 dose level used in Part 3 will be determined by part 1 and 2).
Study NCT00780325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Celecoxib (Celebrex®) capsules: 200 mg; single oral administration (Part 1 and 3)
Study NCT00780325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Placebo capsules: 198 mg silicified microcrystalline cellulose + 2 mg talc, multiple oral administrations (Part 1 and 3)
Study NCT00780325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Naproxen (Naprosyn®) tablets: 500 mg, single oral administration (Part 3)
Study NCT00780325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: Acetazolamide (generic, immediate release) tablets: 250 mg, single oral administration (Part 3)
Study NCT00780325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG100649 (8 mg)
Description: CG100649 capsules: 8 mg, single oral administration (Part 1); CG100649 capsules: dose to be determined, single oral administration (the single CG100649 dose level used in Part 3 will be determined by part 1 and 2).
Study NCT00037921 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bacterial colonization
Study NCT04988347 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Spirulina platensis
Description: Active treatment with Spirulina platensis in capsules containing 530 mg, 1 capsule orally each 8 hours, for 60 days
Study NCT04988347 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Placebo in capsules, 1 capsule orally each 8 hours, for 60 days
Study NCT01228357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRI treated group
Description: Antidepressant administration of SSRI class for 12 weeks under therapeutic dose
Study NCT01228357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: non-SSRI treated group
Description: Antidepressant administration of non-SSRI class for 12 weeks under therapeutic dose
Study NCT02130661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilapladib 25 mg
Description: White, round, biconvex, film coated tablet of 25 mg. Taken orally along with food.
Study NCT02130661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilapladib 250 mg
Description: White, round, biconvex, film coated tablet of 250 mg. Taken orally along with food.
Study NCT02130661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: 100 mg capsule with a blue opaque cap and pink transparent body. Taken orally along with food.
Study NCT00300950 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GI-4000
Description: Heat-killed yeast cell transfected with target ras mutation.
Study NCT00300950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Chemotherapy
Study NCT01806571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Given PO
Study NCT01806571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03848494 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery
Description: Laparoscopic floppy Nissen, laparoscopic-left thoracoscopic Collis-Nissen, laparoscopic gastric fundus wrapped around the stomach
Study NCT01232933 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VPS System
Description: Use of the navigational VPS system during catheter placement
Study NCT03051074 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Floating
Description: Floating supine in a pool saturated with Epsom salt for up to 90 minutes
Study NCT03051074 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparison
Description: Watching a relaxing film for up to 90 minutes
Study NCT01338532 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A 12 week supervised exercise program and patient education
Description: The exercise protocol included exercises from former studies on comparable patient populations. The intensity of the strength- and flexibility exercises meets the American College of Sports Medicine's (ACSM) recommendations for developing and maintaining muscular fitness in adults. Patients was required to exercise for approximately 60 minutes, to-three days a week for 12 weeks. Patient's attendance to the exercise program (compliance) was registered.~All patients included in the study participated in a patient education program which included two individual and three small-group sessions lasting one hour each time.
Study NCT01338532 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient education
Description: All patients included in the study participated in a patient education program which included two individual and three small-group sessions lasting one hour each time.
Study NCT02742805 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D (4,000 IU/day)
Description: High Dose of 4,000 IU/day.
Study NCT04186507 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Smartwatch with integrated Li+ sensor (provided by Spectrophon LTD)
Description: To confirm that Li+ is detectable in sweat using Macroduct Sweat Collection System for sweat collection.~Current studies demonstrate that Li+ can be detected in saliva and in sweat. To confirm it, patients that are on treatment with Li+ will be recruited for this aim; sweat will be collected and checked for Li+ levels.~To develop the algorithm for Spectrophon LTD biosensors for Li+ levels measurement in sweat that will allow assessing the level of Li+ in blood.~To evaluate the accuracy and the efficacy of biosensors developed by Spectrophon LTD for Li+ detection in sweat.~Following positive results in previous objectives, clinical trial will be conducted to estimate the suitability, efficacy and accuracy of developed biosensors for non-invasive detection of Li+ in sweat.
Study NCT00945230 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Re-section of a large left anterior cranial fossa meningioma
Description: Neurosurgical re-section of an incidental large left anterior cranial fossa meningioma
Study NCT03563365 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Replenix Power of 3 Cream with resveratrol
Description: Cosmetic product containing Green Tea Polyphenols, Resveratrol, Caffeine USP, Bisabolol Cucumber extract, Chamomile extract, Rosemary extract, Squalane, Soy Phospholipids
Study NCT03563365 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adapalene and Benzoyl peroxide gel, 0.1%/2.5%
Description: FDA approved topical agent for the treatment of acne
Study NCT02661217 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: LCZ696
Description: LCZ696 film-coated tables were supplied to the investigators. Tablets were taken with a glass of water, and were administered with or without food.~The target dose of LCZ696 was 200 mg twice daily. Starting dose of LCZ696 was either 50 or 100 mg, twice daily. The dose of LCZ696 should be doubled every 2-4 weeks to achieve the target dose of 200 mg twice daily, as tolerated by the patient.
Study NCT02742805 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D (400 IU/day)
Description: Low Dose of 400 IU/day.
Study NCT03563365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene and Benzoyl peroxide gel, 0.1%/2.5%
Description: FDA approved topical agent for the treatment of acne
Study NCT04203420 — intervention group
Intervention type: OTHER
Intervention: screening and confirmatory tests
Description: screening test is a blood test of the ratio of plasma aldosterone concentration(PAC) and direct renin concentration(DRC), confirmatory test is Captopril Challenge test
Study NCT01919216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram
Study NCT01919216 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Citalopram
Study NCT02346513 — intervention group
Intervention type: DEVICE
Intervention: Ceramic on Metal Articulation
Description: Patients have THA with ceramic on metal articulation
Study NCT02346513 — intervention group
Intervention type: DEVICE
Intervention: Non-Ceramic on Metal Articulation
Description: Patients have THA with non-ceramic on metal articulation
Study NCT01716585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Capsule (double-blind treatment period), tablet (open-label treatment period)
Study NCT01716585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABT-450/r/ABT-267
Description: Tablet
Study NCT01716585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABT-333
Description: Tablet
Study NCT02134678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-system therapy
Study NCT02134678 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive therapy
Study NCT02692378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium bicarbonate 500mg capsules
Description: Defined by active substance and brand names not specified in protocol
Study NCT01636128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: difluoromethylornithine
Description: 500 mg oral for 14 days, combined with sulindac for 15 days
Study NCT01636128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulindac
Description: 150 mg oral for 15 days, combined with DFMO for 14 days
Study NCT01620528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elagolix
Description: oral tablet
Study NCT01620528 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral tablet
Study NCT00861328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ON 01910.Na and irinotecan
Description: ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher dose levels after safety evaluation.~The suggested starting dose of Irinotecan is 180 mg/m2 administered by intravenous (IV) infusion over 90 minutes every 2 weeks of a 6-week cycle (3 doses per cycle). Reductions in the starting doses according to recommendations of current approved prescribing information may be considered after review of patients' medical histories and potential tolerances to treatment with the chemotherapy agent.
Study NCT00861328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ON 01910.Na and oxaliplatin
Description: ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher dose levels after safety review of the combination regimen in the previous cohort.~The suggested starting dose of Oxaliplatin is 85 mg/m2 administered by IV infusion over 120 minutes every 2 weeks of a 6-week cycle (3 doses per cycle). Reductions in the starting doses according to recommendations of current approved prescribing information may be considered after review of patients' medical histories and potential tolerances to treatment with the chemotherapy agent.
Study NCT03549559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-Martinostat
Description: Imaging probe for evaluating the activity of histone deacetylase in the heart
Study NCT03549559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 11C-Martinostat
Description: Imaging probe for evaluating the activity of histone deacetylase in the heart
Study NCT03549559 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET-MRI
Description: Siemens PET-MR Scanner (Biograph MMR)
Study NCT03549559 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PET-MRI
Description: Siemens PET-MR Scanner (Biograph MMR)
Study NCT01254825 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor-Canal-Block, Ropivacain
Description: Ultrasound-guided ACB; 30 mL Ropivacain 7,5 mg/mL. Single dose.
Study NCT01254825 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Adductor Canal Block, Placebo (saline)
Description: Ultrasound-guided Adductor Canal Block; 30 mL Saline. Single dose.
Study NCT02036008 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Liver MRI with Gdfos
Description: Participants will receive Gdfos at a dose of 10 mL of 0.25mmol/mL. This will be administered automatically using an MRI-compatible power injector, as a bolus through an intravenous line placed in an antecubital vein at a rate of 1.5 mL/s followed by 25 mL of 0.9% saline flush.~Participants will be imaged using a 3.0 T MRI scanner with an 8 channel body phased array coil utilized covering the entire liver. Images of the liver will be obtained including: axial precontrast phase, axial arterial phase, axial portovenous phase, axial 5 minute delayed phase, axial 10 minute delayed phase, axial 20 minute delayed phase.~This study will be performed within 4 weeks of the MRI study with EcGd.
Study NCT02742805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Standard of care dose.
Study NCT02742805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: Standard of care dose.
Study NCT02748148 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication therapy management
Description: Implementation of a systematic approach to evidence- and personalized-based medicine through a pharmacist-guided medication therapy management service
Study NCT01350167 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Screening
Description: Triphasic CT of the abdomen with and without contrast every 12 months and alpha-fetoprotein testing every 6 months. Repeated until HCC diagnosed for up to 10 years.~Ultrasound of the upper left quadrant every 6 months with alpha-fetoprotein testing every 6 months. Repeated until HCC diagnosed for up to 10 years.